Antifungal activity of *Rhopalurus crassicauda* venom against *Candida* spp.

Umberto Zottich a,*,**,1, Isadora Sousa de Oliveira b,1, Isabela Gobbo Fereira b, Felipe Augusto Cerni c, Bordon Karla de Castro Figueiredo b, Eliane Candidani Arantes b, Valdirene Moreira Gomes d, Germana Bueno Dias e, Manuela Berto Pucca a,*,**

** ABSTRACT **

Fungal infections are becoming a serious problem of human diseases, being one of the most important fungal pathogens the yeast of the genus *Candida*. So far, fungal infection treatment faces different challenges, including the limited number of therapeutic drugs. Scorpions are known to be a valuable source of biologically active molecules, especially of peptide-derived molecules with a variety of biological effects and useful, lead compounds for drug development. Here, we pioneer described the antifungal effect of venom, mucus, and the major toxin (Rc1) from *Rhopalurus crassicauda* scorpion. These results support the potential for Rc1 to be further investigated as a novel antifungal therapeutic to treat *Candida* infections.

** Credit author statement **

UZ performed the experiments and participated in the data interpretation. ISO interpreted the data and drafted the manuscript. IGF, FAC, KCFB, ECA, VMG and GBD participated in the data interpretation and wrote the manuscript. MBP coordinated and designed all the experiments, analyzed and interpreted the data. All authors read, corrected, and approved the final manuscript.

* C. albicans as well as other emerging non albicans species, including *Candida glabrata*, *Candida krusei*, *Candida tropicalis*, and *Candida parapsilosis*, represent an important source of systemic infections throughout the globe. The body sites that *Candida* spp. preferably colonize are the oropharynx, vagina, and skin, especially skin folds (axilla, groin, perineum). It can produce proteolytic enzymes (such as aspartyl proteinases and phospholipases) and toxins (such as mycotoxin) that affect host defenses and enhance their chances of colonizing and invading the host (De Bernardis et al., 1990; Schaller et al., 2003). Also, under favorable conditions, they can enter the bloodstream leading to deep-tissue infections (Conti et al., 2014; Turner and Butler, 2014; Whaley et al., 2016).

Fungal pathogens are a major cause of morbidity and mortality among several patient groups, including those hospitalized in the intensive care unit, solid organ and stem cell transplant recipients, and human immunodeficiency virus (HIV) infected patients. Also, there is a deepening appreciation of genetic risk factors, which may predispose to complications from fungal pathogens that occur among otherwise normal hosts. Most researches regarding novel antifungals have focused on patients who are known to be at greatest risk of invasive fungal infection, since the opportunistic mycoses are a cause of great concern to both clinicians and investigators (Pappas, 2010). The traditional pathogens in this group include *Aspergillus* species, *Cryptococcus* species, the *zygomycetes, Fusarium* species, and *Candida* species (Pfaller and Diekema, 2010).

Fungal pathogens cause life-threatening invasive diseases (e.g. fungemia, meningitis, pneumonia), severe chronic conditions (e.g. chronic pulmonary aspergillosis, allergic bronchopulmonary aspergillosis), complex chronic respiratory conditions (e.g. asthma, chronic obstructive pulmonary disease) and recurrent infections, such as oral and vaginal candidiasis (Brown et al., 2012). In general, these infections are associated with high mortality, and successful clinical outcome requires

1 These authors also contributed equally to this study.

** Handling Editor: Glenn King **

** Keywords:** Rhopalurus crassicauda, scorpion, *Candida albicans, Candida parapsilosis*, Antifungal

https://doi.org/10.1016/j.toxicx.2022.100120

Received 3 December 2021; Received in revised form 18 March 2022; Accepted 19 March 2022

Available online 23 March 2022

2950-1710/© 2022 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
early diagnosis and effective antifungal therapy. However, antimycotic drugs are few, with chemical classes for invasive disease treatment limited to azoles, echinocandins, polyenes, and flucytosine (Odds et al., 2003).

Scorpion venoms are known sources of components able to inhibit microorganism growing. In fact, many antibacterial and antifungal compounds have been isolated from scorpion venoms (Almaya et al., 2012; Machado et al., 2016). In a previous work, authors evaluated 11 scorpion-venom derived non-disulfide-bridged peptides which demonstrated activity against Cryptococcus neoformans, Candida spp., and analogous activity against C. albicans biofilms (Guilhelmelli et al., 2016).

From Tityus species, Tityus serrulatus venom (Tsv) was capable of inhibiting filamentous fungi growth of Aspergillus nidulans, Aspergillus terreus, Penicillium corylophilum, and Penicillium verrucosum (Santussi et al., 2017). Ts1, the major toxin from Tsv, showed a dose-dependent inhibition against C. glabrata (de Melo et al., 2015), and TistH was analyzed towards its analogous activity against C. albicans biofilms (Guilhelmelli et al., 2016).

Inhabiting Amazonian savannah in the Brazilian northern and Guyana Southern (di Caporiacco, 1947; Martins et al., 2021), the scorpion Rhopalurus crassicauda Lourenço, 2002 (synonym Rhopalurus amasonicus Lourenço, 1986 and Rhopalurus laticauda Thorell, 1876) (Esposito et al., 2017; Martins et al., 2021) is a poorly studied species. There is only one study developed by Abreu et al. (2020) revealing the structure and function of the major toxin (Rc1 with ~7 kDa) and the isolation of a hyaluronidase. The same study also explored some activities of the whole venom (e.g. nociception and enzymatic activities) (Abreu et al., 2020). However, no antifungal activity has been explored so far. Based on these facts, this study aimed to describe a novel antifungal activity for R. crassicauda scorpion venom.

R. crassicauda scorpions were collected in Boa Vista - RR (Brazil, 2°49′14.88″ N and 60°40′19.20″ W), The species were kept at Medical School of Federal University of Roraima, received water daily and were fed with cockroaches or crickets twice a month, normally, 5 days prior to venom milking. Venom milking was performed by electrical stimulation of venom gland using electrical pulses (18 V) (Abreu et al., 2020). Pooled venom was stored at –20 °C until its use.

All the procedures involving the scorpions were in accordance with the ethical principles in animal research adopted by Sistema de Autorização e Informação em Biodiversidade (SISBIO), under registration number 57491/9.

The soluble crude venom (supernatant without mucus - 2 mg of proteins) was obtained, applied on a reversed-phase C18 column (10 mm × 250 mm) to obtain Rc1, as described by Abreu et al. (2020). The soluble venom and the toxin Rc1 (which represents 24% of the total protein of the soluble venom) were submitted to antifungal assays.

Yeast cells C. albicans (CE022) and C. parapsilosis (CE002) were preserved in the Laboratórios de Pneumologia e Bioquímica de Microrganismos (LFBM), Universidade Estadual do Norte Fluminense Darcy Ribeiro (UENF), Campos dos Goytacazes, RJ, Brazil, were cultured in Sabouraud broth and quantified in a Neubauer chamber. To monitor the effect of proteins on the growth of yeasts, cells (10^4 in 1 mL Sabouraud broth) were incubated in the presence of the venom (10, 50 and 100 μg/mL), toxin Rc1 or mucus (100 μg/mL), at 28 °C in 200 μL microplates (Broekaert et al., 1990). The positive control was performed with fluconazole 100 μg/mL, getting 100% inhibition (data not shown).

Through the growth kinetics, it was observed that 100 μg/mL of R. crassicauda venom or Rc1 venom (representing 14 μM) were statistically able to inhibit the growth of C. albicans after 24 h, differently from mucus, which did not show the ability to inhibit the growth of the microorganism (Fig. 1A–D).
When the same treatment was performed on C. parapsilosis, it was observed that R. crassicauda venom and mucus, as well as Rc1, were statistically able to inhibit its growth in 24 h, except for the 10 μg/mL of venom (Fig. 2A–D). When at a concentration of 50 μg/mL, C. albicans has a higher growth than the control (Fig. 1A). Dimorphic transitions with the development of pseudo hyphae could explain our failure to detect growth inhibition in this yeast species: pseudo hypha formation might disrupt absorption measurements (Zottich et al., 2011).

Rc1 showed inhibitory activity in the order of magnitude of micromolar concentration, such as those reported for scorpion venom toxins. Serrulin, a glycine-rich native peptide of the T. serrulatus scorpion hemolymph, showed the minimal inhibitory concentration (MIC) of 1.5–3 μM and 3–6 μM against C. albicans and Aspergillus niger, respectively (Oliveira et al., 2019). Ts1, the major toxin from T. serrulatus venom, showed 100% inhibition against A. nidulans from 4.36 μM (Santussi et al., 2017). Stigmurin from T. stigmurus venom showed MIC of 37.5 μM against C. albicans, and its analogues of 4.69–9.38 μM (Parente et al., 2018). Other manuscripts report that the antifungal activity depends on fungal strain (de Melo et al., 2015; Guilhelmelli et al., 2016; Machado et al., 2016) and antifungal agent (Ahmadi et al., 2020). The scorpion venom D-amino acid analogue dKn2–7 from Mesobuthus martensi showed an amphotericin B-like killing kinetics for C. albicans with rapid onset of antifungal activity (Snyder et al., 2021). It is interesting to note that R. crassicauda venom showed inhibitory activity against C. albicans and C. parapsilosis at a concentration 10–50 times lower than that reported for T. serrulatus venom (1 and 5 mg/mL) against the growth of A. nidulans, A. terreus, P. corylophilum, and P. verrucosum (Santussi et al., 2017).

In conclusion, this study pioneer investigated the venom, mucus, and the major toxin of R. crassicauda scorpion for antifungal potential against C. albicans and C. parapsilosis strains. The isolated toxin, Rc1, exhibited the most potent antifungal efficacy against both strains tested. Future studies involving a wider range of R. crassicauda venom-derived toxins and analysis of peptide effects on host tissues are required to better determine if the scorpion venom could be a source of potential and novel antifungal drugs.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

We thank Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP, São Paulo Research Foundation; scholarship to ISO no. 2020/13176-3), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq, The National Council for Scientific and Technological Development, scholarship to MBP no. 307184/2020-0), and the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil (CAPES, Finance Code 001, scholarship to IGF). MBP acknowledges Pro-pesquisa PRPPG-UFPR (Editorial 16/2020).

References

Abreu, C.B., Bordon, K.C.F., Cerni, F.A., Oliveira, I.S., Balañezula, C., Alexandre-Silva, G. M., Zoccal, K.F., Reis, M.B., Wiedel, G.A., Peigneur, S., Pinheiro-Júnior, E.L., Tytgat, J., Cunha, T.M., Quinton, L., Faccioli, L.H., Arantes, E.C., Zottich, U., Pucca, M.B., 2020. Pioneering study on Rhopalurus crassicauda scorpion venom: isolation and characterization of the major toxin and hyaluronidase. Front. Immunol. 11 https://doi.org/10.3389/fimmu.2020.02011.
Ahmadi, S., Knerr, J.M., Argemi, L., Bordon, K.C.F., Pucca, M.B., Cerni, F.A., Arantes, E.C., Caliskan, F., Laustsen, A.H., 2020. Scorpion venom: detriments and benefits. Biomedicines 8, 118. https://doi.org/10.3390/biomedicines8050118.
Almaaytah, A., Zhou, M., Wang, L., Chen, T., Walker, B., Shaw, C., 2012. Antimicrobial cytolytic peptides from the venom of the North African scorpion, Androctonus amoreuxi: biochemical and functional characterization of natural peptides and a single site-substituted analog. Peptides 35, 291–299. https://doi.org/10.1016/j.peptides.2012.03.016.
Brockeart, W.F., Terras, F.R.G., Cammue, B.P.A., Vanderleyden, J., 1990. An automated quantitative assay for fungal growth inhibition. FEMS (Fed. Eur. Microbiol. Soc.) Microbiol. Lett. 69, 55–59. https://doi.org/10.1111/j.1574-6968.1990.tb04174.x.
Brown, G.D., Denning, D.W., Gow, N.A.R., Levitz, S.M., Netea, M.G., White, T.C., 2012. Hidden killers: human fungal infections. Sci. Transl. Med. 4, 165rv13. https://doi.org/10.1126/scitranslmed.3004404.

Conti, H.R., Huppert, A.R., Whibley, N., Gaffen, S.L., 2014. Animal models for candidiasis. Curr. Protoc. Im. 105, 19. https://doi.org/10.1002/0471142735.tm1906s105.

De Bernardis, F., Agatensi, L., Ross, I.K., Emerson, G.W., Lorenzini, R., Sullivan, P.A., Cassone, A., 1990. Evidence for a role for secreted aspartate proteinase of Candida albicans in vulvovaginal candidiasis. J. Infect. Dis. 161, 1276–1283. https://doi.org/10.1093/infdis/161.6.1276.

de Melo, E.T., Estrela, A.B., Santos, E.C.G., Machado, P.R.L., Farias, K.J.S., Torres, T.M., Carvalho, E., Lima, J.P.M.S., Silva-Júnior, A.A., Barbosa, E.G., Fernandes-Pedrosa, M. de F., 2015. Structural characterization of a novel peptide with antimicrobial activity from the venom gland of the scorpion Tityus stigmasurus: Stigmin. Peptides 68, 3–10. https://doi.org/10.1016/j.peptides.2015.03.003.

di Caporiacco, L., 1947. Diagnosi preliminari di specie nuove di Aracnidi della Guiana Britannica. Monit. Zool. Ital. 56, 20–34.

Exposito, L.A., Yamanpiti, H.Y., Souza, C.A., Pinto-da-Rocha, R., Prendini, L., 2017. Systematic Revision of the Neotropical Club-Tailed Scorpions, Physostogon, Rhopalurus, and Troglorhopalurus, Revalidation of Heteroctenus, and Descriptions of Two New Genera and Three New Species (Buthidae, Rhopalurinae). Neotropical club-tailed scorpions, p. 415.

Guilhelmelli, F., Vilela, N., Smidt, K.S., de Oliveira, M.A., da Cunha Morales Álvares, A., Rigonatto, M.C.L., da Silva Costa, P.H., Tavares, A.H., Freitas, S.M. de, Nicolai, A.M., Franco, O.L., Derengowski, L. da S., Schwartz, E.F., Mortari, M.R., Bocca, A.L., Albuquerque, P., Silva-Pereira, L., 2016. Activity of scorpion venom-derived antifungal peptides against planktonic cells of Candida spp. and Cryptococcus neoformans and Candida albicans biofilms. Front. Microbiol. 7 https://doi.org/10.3389/fmicb.2016.01844.

Machado, R.J.A., Estrela, A.B., Nascimento, A.K.L., Melo, M.M.A., Torres-Rêgo, M., Lima, E.O., Rocha, H.A.O., Carvalho, E., Silva-Júnior, A.A., Fernandes-Pedrosa, M.F., 2016. Characterization of Tis1H, a multifunctional peptide from the scorpion Tityus stigmasurus: structure, cytotoxicity and antimicrobial activity. Toxicon 119, 362–370. https://doi.org/10.1016/j.toxicon.2016.06.002.

Martins, J.G., Santos, G.C., Procopio, R.E. de I., Arantes, E.C., Bordon, K. de C.F., 2021. Scorpion species of medical importance in the Brazilian Amazon: a review to identify knowledge gaps. J. Venom. Anim. Toxins Incl. Trop. Dis. 27 https://doi.org/10.1590/1678-9199-JVATITD-2021-0012.

Odds, F.C., Brown, A.J.P., Gow, N.A.R., 2003. Antifungal agents: mechanisms of action. Trends Microbiol 11, 272–279. https://doi.org/10.1016/s0966-842x(03)00117-3.

Oliveira, T. de J., Oliveira, U.C. de, da Silva Junior, P.I., 2019. Serrulin: a glycine-rich bioactive peptide from the hemolymph of the yellow scorpion Tityus serrulatus scorpion. Toxins 11, 517. https://doi.org/10.3390/toxins11050517.

Pupas, P.G., 2010. Opportunistic fungi: a view to the future. Am. J. Med. Sci. 340, 253–257. https://doi.org/10.1097/MAJ.0b013e3181e94e89.

Parente, A.M.S., Daniele-Silva, A., Furtado, A.A., Melo, M.A., Lacerda, A.F., Queiroz, M., Moreno, C., Santos, E., Rocha, H.A.O., Barbosa, E.G., Carvalho, E., Silva-Júnior, A.A., Silva, M.S., Fernandes-Pedrosa, M.D.F., 2018. Analogs of the scorpion venom peptide stigmin: structural assessment, toxicity, and increased antimicrobial activity. Toxins 10, 161. https://doi.org/10.3390/toxins10040161.

Pfäffer, M.A., Diekema, D.J., 2010. Epidemiology of invasive mycoses in North America. Crit. Rev. Microbiol. 36, 1–53. https://doi.org/10.3109/1040841090241444.

Santusso, W.M., Bordon, K.C.F., Rodrigues Alves, A.P.N., Cologna, C.T., Said, S., Arantes, E.C., 2017. Antifungal activity against filamentous fungi of Tst1, a multifunctional toxin from Tityus serrulatus scorpion venom. Front. Microbiol. 8, 984. https://doi.org/10.3389/fmicb.2017.00984.

Schaller, M., Bein, M., Korting, H.C., Baur, S., Hamm, G., Monod, M., Beinhauer, S., Hube, B., 2003. The secreted aspartyl proteinases Sap 1 and Sap 2 cause tissue damage in an in vitro model of vaginal candidiasis based on reconstituted human vaginal epithelium. Infect. Immun. 71, 3227–3234. https://doi.org/10.1128/IAI.71.10.3227-3234.2003.

Snyder, S.S., Gleaton, J.W., Kürsi, D., Chen, W., Millenbaugh, N.J., 2021. Antifungal activity of synthetic scorpion venom-derived peptide analogues against Candida albicans. Int. J. Pept. Res. Therapeut. 27, 281–291. https://doi.org/10.1007/s10989-020-10084-w.

Turner, S.A., Butler, G., 2014. The Candida pathogenic species complex. Cold Spring Harb. Perspect. Med. 4, a019778. https://doi.org/10.1101/cshperspect.a019778.

Whaley, S.G., Berkow, E.L., Rybak, J.M., Nishimoto, A.T., Barker, K.S., Rogers, P.D., Turner, S.A., Butler, G., 2014. The Candida pathogenic species complex. Cold Spring Harb. Perspect. Med. 4, a019778. https://doi.org/10.1101/cshperspect.a019778.

Whaley, S.G., Berkow, E.L., Rybak, J.M., Nishimoto, A.T., Barker, K.S., Rogers, P.D., 2016. Azole antifungal resistance in Candida albicans and emerging non-albicans Candida species. Front. Microbiol. 7, 2173. https://doi.org/10.3389/fmicb.2016.02173.

Zottich, U., das Cunha, M., Carvalho, A.O., Dias, G.B., Silva, N.C.M., Santos, I.S., do Nascimento, V.V., Miguel, E.C., Machado, O.L.T., Gomes, V.M., 2011. Purification, biochemical characterization and antifungal activity of a new lipid transfer protein (LTP) from Coffea canephora seeds with α-amylase inhibitor properties. Biochim. Biophys. Acta Gen. Subj. 1810, 375–383. https://doi.org/10.1016/j.bbadis.2010.12.002.